ENANTA PHARMACEUTICALS, INC Derivative Liability, Fair Value, Gross Liability
ENANTA PHARMACEUTICALS, INC (ENTA) had Derivative Liability, Fair Value, Gross Liability of $1.68 million as of 2014-06-30, per its 10-Q filed 2014-08-12.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2014-08-12
- 2014-06-30: Derivative Liability, Fair Value, Gross Liability $1.68M.
- 2014-03-31: Derivative Liability, Fair Value, Gross Liability $1.62M.
- 2013-12-31: Derivative Liability, Fair Value, Gross Liability $1.64M.
- 2013-09-30: Derivative Liability, Fair Value, Gross Liability $1.62M.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2014-06-30 | $1.68M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $1.62M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $1.64M 10-Q · filed 2014-02-13 |
| 2013-09-30 | $1.62M 10-Q · filed 2014-08-12 |
| 2013-06-30 | $1.78M 10-Q · filed 2013-08-12 |
| 2013-03-31 | $1.77M 10-Q · filed 2013-05-15 |
| 2012-09-30 | $2.00M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |